TY - JOUR
T1 - ACOG COMMITTEE OPINION No. 727 SUMMARY
T2 - Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With Cancer
AU - Committee on Gynecologic Practice
AU - Witkop, Catherine
N1 - Publisher Copyright:
Copyright © by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
PY - 2018/1
Y1 - 2018/1
N2 - “Cascade testing” refers to the performance of genetic counseling and testing in blood relatives of individuals who have been identified with specific genetic mutations. Testing protocols and other interventions may save lives and improve health and quality of life for these family members. Obstetrician-gynecologists should know who is eligible for cascade testing and should use all available resources to ensure that cascade testing is offered and occurs in a timely manner. Despite the clear health benefits for specific populations and individuals, obstetrician-gynecologists should be aware of the potential barriers to cascade testing and should know which options can help patients overcome those barriers. Such barriers, however, may be overcome with health care provider awareness and participation in local and state initiatives to improve implementation of cascade testing. Resources (available within federal and state agencies, professional societies, and in advocacy and community groups) are critical to the successful implementation of cascade testing. This Committee Opinion focuses specifically on cascade testing and the role of the obstetrician-gynecologist in clinical and public health efforts to increase identification of women with hereditary cancer syndromes.
AB - “Cascade testing” refers to the performance of genetic counseling and testing in blood relatives of individuals who have been identified with specific genetic mutations. Testing protocols and other interventions may save lives and improve health and quality of life for these family members. Obstetrician-gynecologists should know who is eligible for cascade testing and should use all available resources to ensure that cascade testing is offered and occurs in a timely manner. Despite the clear health benefits for specific populations and individuals, obstetrician-gynecologists should be aware of the potential barriers to cascade testing and should know which options can help patients overcome those barriers. Such barriers, however, may be overcome with health care provider awareness and participation in local and state initiatives to improve implementation of cascade testing. Resources (available within federal and state agencies, professional societies, and in advocacy and community groups) are critical to the successful implementation of cascade testing. This Committee Opinion focuses specifically on cascade testing and the role of the obstetrician-gynecologist in clinical and public health efforts to increase identification of women with hereditary cancer syndromes.
UR - http://www.scopus.com/inward/record.url?scp=85040103481&partnerID=8YFLogxK
U2 - 10.1097/AOG.0000000000002451
DO - 10.1097/AOG.0000000000002451
M3 - Article
C2 - 29266071
AN - SCOPUS:85040103481
SN - 0029-7844
VL - 131
SP - 194
EP - 195
JO - Obstetrics and gynecology
JF - Obstetrics and gynecology
IS - 1
ER -